Farshad Guirakhoo - Jan 13, 2022 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role
(Former) Chief Scientific Off.
Signature
/s/ Rene Paula Molina, attorney-in-fact for Farshad Guirakhoo
Stock symbol
VAXX
Transactions as of
Jan 13, 2022
Transactions value $
$33,428
Form type
4
Date filed
8/29/2022, 04:45 PM
Previous filing
Nov 15, 2021
Next filing
May 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VAXX Class A common stock Options Exercise $5.7K +10K $0.57* 10K Jan 13, 2022 Direct
transaction VAXX Class A common stock Options Exercise $11.4K +20K +100% $0.57* 40K Jul 29, 2022 Direct F1
transaction VAXX Class A common stock Options Exercise $14.8K +26K +65.01% $0.57* 66K Aug 15, 2022 Direct
transaction VAXX Class A common stock Options Exercise $1.5K +2.64K +4% $0.57* 68.6K Aug 22, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Stock option (right to buy) Options Exercise $0 -10K -7.89% $0.00 117K Jan 13, 2022 Class A common stock 10K $0.57 Direct F2
transaction VAXX Stock option (right to buy) Options Exercise $0 -20K -18.74% $0.00 86.7K Jul 29, 2022 Class A common stock 20K $0.57 Direct F2, F3
transaction VAXX Stock option (right to buy) Options Exercise $0 -26K -29.98% $0.00 60.7K Aug 15, 2022 Class A common stock 26K $0.57 Direct F2
transaction VAXX Stock option (right to buy) Options Exercise $0 -2.64K -4.35% $0.00 58.1K Aug 22, 2022 Class A common stock 2.64K $0.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Farshad Guirakhoo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock.
F2 These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.
F3 The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options.